Study Suggests DLCO as Indicator of Survival in Group 3 Pulmonary Hypertension
Low diffusing capacity of the lung for carbon monoxide (DLCO) is a key indicator of mortality in group 3 pulmonary hypertension (PH), according to ... Read more
Updates
-
-
Switching from Tyvaso to Uptravi Safe, Convenient for PAH Patients, Phase 3b Study Finds
Switching treatment from United Therapeutics’ Tyvaso (inhaled treprostinil) to Actelion’s Uptravi (oral selexipag) is safe and considered convenient by patients with pulmonary ... Read more -
Reminders for the Days I Feel Like I’m Not Doing Enough
Some days, I feel well enough to make the most out of each day. On these days, I find the energy to clean the ... Read more -
CTEPH Software Receives FDA’s Breakthrough Device Designation
The U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to software being developed by Bayer and Merck — known as MSD outside the ... Read more -
Uptravi, PAH Treatment, Now Publicly Funded in 9 of 10 Canadian Provinces
Uptravi (selexipag) is now available with public funding for pulmonary arterial hypertension (PAH) patients in Canada living in nine of the country’s 1o provinces, ... Read more
-
Morphogen-IX Announces MGX292 as Treatment Candidate for PAH
Biotechnology company Morphogen-IX recently announced that it will be further developing MGX292 as its treatment ... -
PhaseBio Advances New Phase 2b Trial to Test PB1046 in Patients with PAH
PhaseBio Pharmaceuticals started dosing its investigational compound PB1046 in patients with pulmonary arterial hypertension ... -
An Invisible Illness and the PHight of Our Lives
Wonder Woman has an invisible jet. Harry Potter has an invisibility cloak. I have ... -
Specific Bone Marrow Cells Drive PAH Development, Blocking Serotonin Receptors a Potential Treatment, Study Suggests
A subset of bone marrow cells known as proangiogenic cells (PACs) may drive the ... -
First Clinical Site Announced for Phase 2 Trial Testing Levosimendan for PH Linked to Heart Disease
The Stanford University School of Medicine is the first clinical site for a Phase ... -
Raising Levels of Immune Cell Receptor Known as TLR3 May Better Treat PH, Early Study Reports
A receptor protein present in immune cells is a potential target for treating pulmonary ...
Subscribe to our mailing list
Get regular updates delivered to your email box.
Thanks! Please check your email for a confirmation email.
Being Patient Is Difficult when You’re a Patient
Columns, Recharged and Rewired - a Column by Brittany Foster
“You just have to be patient.” I can’t begin to count how many times I’ve heard this throughout my years of managing chronic illness. Although I have 26 years of experience with doctor’s appointments, testing, surgeries, medications, and the ... Read more